Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Jean-Robert Grenier who wrote (472)	10/7/1998 12:06:00 PM
From: alex gurion	Read Replies (1) \| Respond to of 783

Glaxo was up $1.625 based on FDA panel recommendation. GLX has 1.79 Billion shares outstanding. It means GLX has added $2.908 Billion to its market capitalization. BCHE has 108 million shares and market cap of $1.91 Billion. It means that GLX has increased its market cap on this news more than the total cap of BCHE. GLX P/E ratio is 33 which means investors pay $33 for each $1 of GLX earnings. Currently GLX pays about $130 Million in royalties to BCHE. Let's say royalty will increase by $130 Million after lamivudine will hit the market. $260 Million of royalty is a net expense for GLX. In my humble opinion GLX can easily pay 33 x 260 = $8.58 Billion for BCHE based just on royalties payments plus get research plus all other stuff for free. $8.58 Billion / 108 Million shares = $79.4 $/share Any objections?